title: Adult genitourinary sarcoma: the 25-year Memorial Sloan-Kettering experience.
abstract: OBJECTIVE
  Urological sarcomas are rare. We describe a continued single institutional experience during 25 years.
  
  
  METHODS
  The records from July 1977 to July 2003 were reviewed of all patients at our institution with sarcoma arising in the urinary tract or male genital system who were 16 years or older at diagnosis.
  
  
  RESULTS
  The primary tumor site in 131 patients was the bladder in 20, the kidney in 26, paratesticular in 57, the prostate in 21 and other in 7. Median followup was 4.0 years. The most common histological subtypes were leiomyosarcoma in 29% of cases and liposarcoma in 26%. Median tumor size was 7 cm and 78% of lesions were high grade. Of the patients 28 (21%) presented with metastatic disease and their median survival was 1.4 years compared to 10.7 years in patients without metastatic disease (p < 0.0001). Disease specific survival was 56% and 42% at 5 and 10 years, respectively and median survival was 7.6 years. On univariate analysis unfavorable prognostic variables for disease specific survival were metastasis at presentation, high tumor grade, a lack of leiomyosarcoma and liposarcoma histological subtypes, prostate sarcoma and large tumor size, incomplete surgical resection and positive surgical margin. Patient sex, age and surgical margin status were not significant predictors. On multivariate analysis 2 variables remained significant predictors of disease specific survival, including tumor size (HR 1.1, 95% CI 1.02 to 1.17) and absent metastasis at diagnosis (HR 4.9, 95% CI 1.4 to 17.2).
  
  
  CONCLUSIONS
  Predictors of disease specific survival include local disease at presentation, complete tumor resection and tumor grade, size, location and histological subtype. With adequate surgical treatment most patients who presented with primary disease and underwent complete surgical resection achieved prolonged disease specific survival.
authors.affiliation: Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
authors.forename: Zohar A
authors.initials: ZA
authors.lastname: Dotan
authors.forename: Raanan
authors.initials: R
authors.lastname: Tal
authors.forename: Dragan
authors.initials: D
authors.lastname: Golijanin
authors.forename: Mark E
authors.initials: ME
authors.lastname: Snyder
authors.forename: Cristina
authors.initials: C
authors.lastname: Antonescu
authors.forename: Murray F
authors.initials: MF
authors.lastname: Brennan
authors.forename: Paul
authors.initials: P
authors.lastname: Russo
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D012509:Sarcoma / Q000401:mortality / Q000628:therapy; D015996:Survival Rate; D013997:Time Factors; D014565:Urogenital Neoplasms / Q000401:mortality / Q000628:therapy